sugammadex

Competitive Landscape

0 competitors in Neuromuscular Blockade

View Full Landscape

Drug Information

Target Indication

Neuromuscular Blockade

Clinical Trial

NCT01050543

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/23/2023

Sugammadex Piramal

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years.

View on EMA

EMA5/26/2023

Sugammadex Adroiq

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

View on EMA

EMA1/10/2023

Sugammadex Amomed

Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years.

View on EMA

EMA7/15/2022

Sugammadex Fresenius Kabi

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

View on EMA

EMA11/15/2021

Sugammadex Mylan

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

View on EMA

EMA7/25/2008

Bridion

Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK-8748Phase 3

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis